BioSpace News Archive

The Glucose Meter Market size is expected to reach USD 21.27 Billion in 2030 and register a revenue CAGR of 9.5% over the forecast period, according to latest report by Reports and Data

The global medical foods market size is expected to reach USD 33.85 Billion in 2030 and register a revenue CAGR of 5.4% over the forecast period, according to latest report by Reports and Data.

The Center for Breakthrough Medicines (CBM) in partnership with the Discovery Labs announced today the acceleration of plans to build capacity to manufacture more than 10,000 patient therapies in direct response to the critical shortage of cell therapy supply, which will help patients win their courageous battles against cancer.

The global ultrasound gel market size is expected to reach USD 126.2 Million in 2030 and register a revenue CAGR of 3.4% over the forecast period, according to a latest report by Reports and Data.

Immunicom, Inc., a privately held clinical-stage biotechnology company with a transformative immuno-oncology platform, has been awarded $2 million by the National Cancer Institute and National Institutes of Health to initiate its first US-based clinical trial at the Baylor College of Medicine in Houston, Texas.

The vast majority and types of fluoropolymers, which are part of the per- and polyfluoroalkyl substance family, meet internationally recognized criteria for being considered polymers of low concern, a designation for compounds that are expected to have insignificant environmental and human health impacts, according to a new scientific paper.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced that its chief medical officer, Dr. Loren Clarke, will present study data illustrating how genomic technology can enhance melanoma detection and improve patient care at America’s Health Insurance Plans 2022.

Day One Biopharmaceuticals, Inc. announced the pricing of its upsized underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share.

MedX appoints Naman Demaghlatrous to its Board of Directors.

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced the online publication of a new study evaluating the efficacy and safety of ZYNRELEF.